| 764518 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
51 A novel cross-site analysis of Vectra® Polaris™ multiplex fluorescence PD-1/PD-L1 immunohistochemistry on colorectal cancer with high and low microsatellite instability |
2021-11-01 |
10.1136/jitc-2021-sitc2021.051 |
Pollan Sara, Remeniuk Bethany, Hanifi Arezoo, Roman Kristin, Hopkins Bei, Monteiro Natalie, Nunns Harry, Parnell Erinn, William Josette, Au Qingyan |
| 764517 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
49 Highly multiplexed detection of critical immune checkpoints and immune cell subtypes in cancerous FFPE tissues using CODEX |
2021-11-01 |
10.1136/jitc-2021-sitc2021.049 |
Shang Olive, Gordon Judi, Nikulina Nadya, Mistry Sejal, Singh Jasmine, Zong Hailing, Yuan Jessica, Blackmer Trillium, Locke Darren, Braubach Oliver, Kennedy-Darling Julia, Miller Peter |
| 764516 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
48 Immune environment correlates with NSCLC and CRC patient survival |
2021-11-01 |
10.1136/jitc-2021-sitc2021.048 |
Miller Dannah, Nguyen Huong, Hieber Kate, Caldwell Charles, Gianani Roberto |
| 764515 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
47 Tertiary lymphoid structures (TLS) in desmoplastic melanomas (DM) differ from non-DM-associated TLS by their intratumoral location and enhanced immune activity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.047 |
Mauldin Ileana, Stowman Anne, Hickman Alexandra, Mahmutovic Adela, Gru Alejandro, Lynch Kevin, Young Samuel, Meneveau Max, Wages Nolan, Engelhard Victor, Slingluff Craig |
| 764514 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
46 Proximity between cytotoxic antigen-experienced T cells and tumor cells is associated with improved clinical outcomes in early-stage NSCLC |
2021-11-01 |
10.1136/jitc-2021-sitc2021.046 |
Luo Qianyun, Parra Edwin, Negrao Marcelo, Akhave Neal, Bayley Erin, Mitchell Kyle, Zhang Jianjun, Heymach John, Sepesi Boris, Wistuba Ignacio, Gibbons Don, Reuben Alexandre |
| 764513 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
800 Dual targeting of CTLA-4 and CD47 on Treg cells rejuvenates immunity against solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.800 |
Zhang Anli, Ren Zhenhua, Tseng Kuo-fu, Liu Xiajuan, Li Huiyu, Lu Changzheng, Cai Yueqi, Minna John, Fu Yang-Xin |
| 764512 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
799 Neoantigen-cytokine-chemokine multifunctional natural killer cell engager for immunotherapy of solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.799 |
Yao Xue, Matosevic Sandro |
| 764511 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
798 CDX-585, A bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways |
2021-11-01 |
10.1136/jitc-2021-sitc2021.798 |
Vitale Laura, Murphy Michael, Xia Collin, Peng Zeyu, O'Neill Thomas, Natoli Ed, Lillquist Jay, Crew Linda, Wasiuk Anna, Weidlick Jeff, Widger Jenifer, Mills-Chen Laura, Crocker Andrea, Patterson Colleen, Boyer James, Baronas April, Hammond Russell, Davis Hugh, Ma Mark, Goldstein Joel, Thomas Lawrence, Alvarado Diego, Marsh Henry, Keler Tibor |
| 764510 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
797 A novel anti-PD-1/IL15 bi-functional antibody with robust anti-tumor activity in multiple solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.797 |
Lu Dan, Chang Tzu-Pei, Polonskaya Zhanna, Martomo Stella, Luna Xenia, Zhang Zhikai, Ng Stanley, Patel Jeegar |
| 764509 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
796 ALG.APV-527: a 5T4 tumor directed bispecific approach utilizing ADAPTIRTM technology designed for conditional 4-1BB T cell/NK agonism against solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.796 |
Nelson Michelle, Sundstedt Anette, Coaña Yago Pico de, Lucas Ashly, Nilsson Anneli, Ljung Lill, Chunyk Allison, Schultz Lena, McMahan Catherine, Gross Jane, Frizell Sara, Ramos Hilario, Ellmark Peter |
